GlassScriptPhysician profile
Delaney Herper
NPI 1235736794
$3,065.53
in general payments reported to CMS, 2019-2025
21 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,469 · 2022: $270 · 2023: $896 · 2024: $291 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $493.41 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $466.30 | 2021-2023 | Spravato |
| Abbvie INC. | $465.45 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.78 | 2021-2025 | Caplyta |
| Alkermes, INC. | $273.82 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $192.83 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $186.85 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $169.59 | 2021 | |
| Almatica Pharma LLC | $68.01 | 2021-2025 | Loreev Xr |
| Corium, LLC | $65.17 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $49.48 | 2021 | |
| Eisai INC. | $48.14 | 2021 | |
| Bausch Health US, LLC | $43.64 | 2021 | |
| Indivior INC. | $36.49 | 2023-2024 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $36.09 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.64 | 2023 | Qelbree |
| Neos Therapeutics, LP | $20.14 | 2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $17.52 | 2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $15.52 | 2021 | |
| Merck Sharp & Dohme LLC | $13.73 | 2021 | |
| Lundbeck LLC | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaney Herper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.